Skip to main content

Table 3 Rate of responding patients according to baseline characteristics

From: Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial

Variable no. of patients response rate
  at risk responding (95% exact CI)
Age    
   <65 40 21 52.5 (36.1–68.5)
   65 or more 10 3 30.0 (6.7–65.2)
Histotype    
   Ductal 41 20 48.8 (32.9–64.9)
   Lobular or other 9 4 44.4 (13.7–78.8)
ER status    
   Negative 19 9 47.4 (24.5–71.1)
   Positive 30 14 46.7 (28.3–65.7)
Performance status    
   0 41 22 53.7 (37.4–69.3)
   1 or 2 9 2 22.2 (2.8–60.0)
Time from breast cancer diagnosis    
   <2 years 19 12 63.2 (38.4–83.7)
   2 years or more 31 12 38.7 (21.8–57.8)
Previous chemotherapy    
   No 9 4 44.4 (13.7–78.8)
   Yes 41 20 48.8 (32.9–64.9)
By type of drugs    
CMF 4 2 50.0 (6.8–93.2)
with anthracycline 24 13 54.2 (32.8–74.5)
with anthracycline and taxane 13 5 38.5 (13.9–68.4)
By number of lines of chemotherapy    
one line 26 13 50.0 (29.9–70.1)
two lines 15 7 46.7 (21.3–73.4)
Extension of disease    
   By number of involved organs    
1 27 13 48.1 (28.7–68.0)
2 16 7 43.7 (19.7–70.1)
3 7 4 57.1 (18.4–90.1)
   By dominant metastatic site    
soft tissues 13 7 53.8 (25.1–80.8)
viscera 37 17 45.9 (29.5–63.1)